Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine.
BACKGROUND
Antihistamines (H1-receptor antagonists) act by competitive antagonism of histamine at H1-receptors. In addition, high concentrations of some antihistamines inhibit allergen-induced histamine release from mast cells in vitro.


OBJECTIVE
The purpose of this study was to determine the effect of intranasal azelastine or systemic cetirizine (both potent antihistamines) on the allergen-induced release of mast-cell mediators from the human nasal mucosa in vivo.


METHODS
Patients allergic to birch pollen (n = 11) and control subjects not allergic to birch pollen (n = 5) were included in a randomized, double-blind, placebo-controlled, 3-way crossover study outside the pollen season. Each subject was treated with azelastine nasal spray 0.14 mg per nostril twice daily, cetirizine tablets 10 mg every day, or placebo for 1 week using a double-dummy design. At the end of each treatment period, nasal allergen challenges were performed, and the number of sneezes were counted. In addition, nasal lavage fluid was collected, and the levels of mast-cell mediators (histamine and tryptase) were measured.


RESULTS
The allergen challenge of patients allergic to pollen produced sneezing and a significant increase in the levels of histamine and tryptase. The challenge of subjects not allergic to pollen produced no such response. Azelastine and cetirizine significantly reduced allergen-induced sneezing and the associated increase in histamine and tryptase levels. No significant differences were found between the azelastine and cetirizine treatments.


CONCLUSIONS
Pretreatment with azelastine or cetirizine inhibits the allergen-induced release of mast-cell mediators from the human nasal mucosa. Our results are consistent with the hypothesis that both antihistamines reduce mediator release from nasal mucosa mast cells in vivo. However, further studies are necessary to test this hypothesis.
D000281:Administration, Intranasal; D000328:Adult; D017332:Cetirizine / Q000494:pharmacology / Q000627:therapeutic use; D053818:Chymases; D004311:Double-Blind Method; D005260:Female; D006632:Histamine / Q000032:analysis*; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis*; D008297:Male; D008407:Mast Cells / Q000737:chemistry; D017817:Nasal Lavage Fluid / Q000737:chemistry*; D009299:Nasal Provocation Tests; D010793:Phthalazines / Q000008:administration & dosage / Q000627:therapeutic use; D011292:Premedication; D012697:Serine Endopeptidases / Q000032:analysis*; D013997:Time Factors; D053802:Tryptases